In liver cancer, an anti-AFP scFv (alpha-fetoprotein, a hepatocellular carcinoma marker) combined with administered paclitaxel, resulted in a decrease in the density of tumor vessels and a greater decrease in tumor size in mice when compared with only the administration of paclitaxel [133]. The gene discussed is AFP; the disease is liver cancer.